Exelixis (52)

Browse by Contract Category

Contracts

Cash Compensation Information for Non-Employee Directors (Filed With SEC on November 1, 2022)
Seventh Amendment dated May 16, 2022, to Lease Agreement dated May 2, 2017, between SCG Harbor Bay Parkway Phase I, LLC and Exelixis, Inc (Filed With SEC on August 9, 2022)
Second Amendment dated May 7, 2019, to Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited (Filed With SEC on May 10, 2022)
Offer Letter Agreement, dated (Filed With SEC on February 18, 2022)
Description of the Common Stock of Exelixis, Inc. Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on February 18, 2022)
Cash Compensation Information for Non-Employee Directors (Filed With SEC on August 9, 2022)
Exelixis, Inc. 2017 Equity Incentive Plan (Filed With SEC on August 9, 2022)
Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited (Filed With SEC on May 10, 2022)
Third Amendment dated December 10, 2021, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on February 18, 2022)
Form of Indemn (Filed With SEC on February 18, 2022)
Specimen Common Stock Certificate (Filed With SEC on August 5, 2021)
Second Amendment dated September 14, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on May 6, 2021)
Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on May 6, 2021)
First Amendment dated December 20, 2016, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on May 6, 2021)
First Amendment dated October 26, 2017, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on May 6, 2021)
Third Amendment dated October 26, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on May 6, 2021)
Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on May 6, 2021)
Sixth Amendment dated December 11, 2020, to Lease Agreement dated May 2, 2017, between SCG Harbor Bay Parkway Phase I, LLC (as successor in interest to Waterfront EDP, LLC) and... (Filed With SEC on February 11, 2021)
Form of Stock Option Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan (Filed With SEC on February 11, 2021)
Third Amendment dated September 3, 2020, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited (Filed With SEC on November 5, 2020)
Exelixis, Inc. 2017 Equity Incentive Plan (Filed With SEC on August 6, 2020)
Second Amendment dated May 7, 2020, to the Supplement to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Bristol-Myers Squibb... (Filed With SEC on August 6, 2020)
Form of Restricted Stock Unit Agreement (Non-Employee Director) under the Exelixis, Inc. 2017 Equity Incentive Plan (Filed With SEC on August 6, 2020)
Form of Restricted Stock Unit Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan (Filed With SEC on August 6, 2020)
Form of Stock Option Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan (Filed With SEC on August 6, 2020)
Exelixis, Inc. 2016 Inducement Award Plan (Filed With SEC on August 6, 2020)
Exelixis, Inc. 2014 Equity Incentive Plan (Filed With SEC on August 6, 2020)
Non-Employee Director Equity Compensation Policy (Filed With SEC on May 5, 2020)
Supplement dated December 18, 2019, to the Joint Clinical Research Agreement dated December 18, 2019, by and among Exelixis, Inc., F. Hoffmann-La Roche Ltd and Ipsen Pharma SAS (Filed With SEC on February 25, 2020)
Joint Clinical Research Agreement dated December 18, 2019, by and between Exelixis, Inc. and F. Hoffmann-La Roche Ltd (Filed With SEC on February 25, 2020)
Amendment No. 3 dated November 22, 2019, to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Meyers Squibb Company (Filed With SEC on February 25, 2020)
First Amendment dated January 16, 2020, to Lease Agreement dated May 2, 2017, between Alameda BTS EDP, LLC (as successor in interest to Ernst Development Partners, Inc.) and... (Filed With SEC on February 25, 2020)
Fifth Amendment dated January 16, 2020, to Lease Agreement dated May 2, 2017, between Waterfront EDP, LLC (as successor in interest to Hillwood Enterprises, L.P.) and Exelixis, Inc (Filed With SEC on February 25, 2020)
Cash Compensation Information for Non-Employee Directors (Filed With SEC on February 25, 2020)
Description of the Common Stock of Exelixis, Inc. Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on February 25, 2020)
Lease Agreement dated October 25, 2019, between Ernst Development Partners, Inc. and Exelixis, Inc (Filed With SEC on October 30, 2019)
Fourth Amendment dated August 30, 2019, to Lease Agreement dated May 2, 2017, between Hillwood Enterprises, L.P. (as successor in interest to Ascentris 105, LLC) and Exelixis, Inc (Filed With SEC on October 30, 2019)
Amendment No. 2 dated August 15, 2019 to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Myers Squibb Company (Filed With SEC on October 30, 2019)
Second Amendment dated May 17, 2019, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on July 31, 2019)
Second Amendment dated May 17, 2019, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited (Filed With SEC on July 31, 2019)
Form of Restricted Stock Unit Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan (Filed With SEC on May 1, 2019)
Form of Stock Option Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan (Filed With SEC on May 1, 2019)
Policy for Recoupment of Variable Compensation (Filed With SEC on May 1, 2019)
Cash Compensation Information for Non-Employee Directors (Filed With SEC on May 1, 2019)
Non-Employee Director Equity Compensation Policy (Filed With SEC on May 1, 2019)
Amendment No. 1 dated March 8, 2019 to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Meyers Squibb Company (Filed With SEC on May 1, 2019)
Third Amendment to Lease Agreement, dated April 1, 2019, between Exelixis, Inc. and Ascentris 105, LLC (Filed With SEC on April 5, 2019)
Exelixis, Inc. 2016 Inducement Award Plan (Filed With SEC on February 22, 2019)
Exelixis, Inc. 2014 Equity Incentive Plan (Filed With SEC on February 22, 2019)
Cash Compensation Information for Non-Employee Directors (Filed With SEC on February 22, 2019)
Amendment #3 dated May 29, 2018, to Cooperative Research and Development Agreement for Extramural-PHS Clinical Research by and between The U.S. Department of Health and Human... (Filed With SEC on February 22, 2019)
Exelixis, Inc. 2011 Equity Incentive Plan (Filed With SEC on February 22, 2019)